Valeo Financial Advisors LLC Lowers Stock Position in Novo Nordisk A/S (NYSE:NVO)

Valeo Financial Advisors LLC decreased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 14.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 27,715 shares of the company's stock after selling 4,519 shares during the quarter. Valeo Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $1,925,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL lifted its stake in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S during the 1st quarter valued at $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $29,000. Finally, Transce3nd LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $33,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 2.9%

Shares of NVO traded down $2.08 during midday trading on Friday, hitting $68.93. 6,510,099 shares of the stock were exchanged, compared to its average volume of 7,302,188. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $143.49. The stock has a fifty day simple moving average of $70.36 and a 200 day simple moving average of $75.21. The firm has a market cap of $307.77 billion, a P/E ratio of 20.39, a P/E/G ratio of 1.36 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion for the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on NVO shares. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Finally, BNP Paribas began coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.